^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LNC-003

    i
    Other names: LNC-003
    Associations

    News

    Trials
    Company:
    Rebus
    Drug class:
    Adenosine A2A receptor antagonist, Adenosine A2B receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    Development of [Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. (PubMed, Eur J Nucl Med Mol Imaging)
    In this study, [Lu]Lu-LNC1003 was successfully synthesized with high radiochemical purity and stability. High binding affinity and PSMA targeting specificity were identified in vitro and in vivo. With greatly enhanced tumor uptake and retention, [Lu]Lu-LNC1003 has the potential to improve therapeutic efficacy using significantly lower dosages and less cycles of Lu that promises clinical translation to treat prostate cancer with various levels of PSMA expression.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • LNC-003